- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05048940
Efficacy, Safety, and Immunogenicity of Vaccine Reimmunization With a Third Homologous Versus Heterologous Dose Against COVID-19 in Patients Undergoing Solid Organ Transplantation. (REIN-TX)
Randomized, Open-label, Adaptive, Controlled, Phase III Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of Reimmunization With Third Dose of Homologous vs. Heterologous Vaccine Against COVID-19 in Patients Undergoing Solid Organ Transplantation: Liver, Heart, Kidney and Lung.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The main objective of this trial is to evaluate the immunogenicity of reimmunization against SARS-CoV-2 in patients undergoing solid organ transplantation with heterologous revaccination, testing whether in patients who received two doses of Spikevax Moderna vaccine there is a significant increase at 28 days in their antibody titers against SARS-CoV-2 after receiving a dose of Janssen.
The secondary objectives of this trial are:
- To evaluate the efficacy of reimmunization against SARS-CoV-2 in subjects undergoing solid organ transplantation, in terms of incidence of infection and severity of COVID-19 after revaccination in the transplanted patient.
- To gain insight into the humoral and cellular immune response conferred by the sequential combination of both homologous and heterologous vaccination over one year, as well as its duration in subjects undergoing solid organ transplantation.
- To evaluate the safety of vaccines against SARS-CoV-2 in subjects undergoing solid organ transplantation.
- To determine the potential existence of differences in humoral (Anti S Ac) and cellular immune response depending on the immunosuppression regimen.
- To evaluate the occurrence of side effects, including rejection and anti-HLA and DSA antibodies after revaccination.
Study Type
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: María del Mar García Saiz
- Phone Number: 942 20 33 33
- Email: mmar.garcia@scsalud.es
Study Contact Backup
- Name: Lucía Lavín Alconero
- Phone Number: 942 20 33 89
- Email: eclinicos5@idival.org
Study Locations
-
-
Cantabria
-
Santander, Cantabria, Spain, 39008
- Hospital Universitario Marques de Valdecilla
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients who underwent solid organ transplantation prior to revaccination against COVID-19.
- Patients who have received the full COVID-19 vaccination regimen with Spikevax (Moderna) vaccine, with a minimum of 8 weeks having elapsed from the second dose to the time of trial initiation.
- Age > 18 years.
- All participants must have previously agreed to participate in the study by signing the informed consent form.
Exclusion Criteria:
- Having suffered SARS-CoV-2 infection at any time prior to inclusion in the study.
- Subjects without solid organ transplantation or with a different solid organ (e.g. pancreas transplantation) and without any type of immunosuppression (immunocompetent non-transplanted) from the general population.
- Age < 18 years
- Temperature of at least 38°C in the 24 hours prior to immunization or other clinically relevant acute symptomatology.
- Clinical manifestations compatible with COVID-19 infection at the time of evaccination.
- Known allergy or history of anaphylaxis or other serious adverse events to the administration of vaccines or their excipients.
- Any other condition that contraindicates vaccination against SARSCov2, including pregnancy.
- Having presented graft rejection in the 15 days prior to the start of the study.
- Any condition or situation that may interfere with the ability to maintain adherence to study procedures and visits.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HETEROLOGOUS VACCINE
COVID-19 Vaccine Janssen, injectable suspension
|
0.5 ml millilitre(s) Intramuscular use
Other Names:
|
Active Comparator: HOMOLOGOUS VACCINE
Spikevax (Moderna), injectable dispersion
|
0.5 ml millilitre(s) Intramuscular use
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in the production of anti-S1-RBD IgG antibodies.
Time Frame: 28 days
|
Positivity for comparison before and after revaccination and according to homologous or heterologous vaccination will be quantified in the laboratory method units.
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the presence of activated T cells specific for SARS-CoV-2 (Sprotein).
Time Frame: 1 year
|
T-cell response to SARS-CoV-2 will be analyzed by flow cytometry.
|
1 year
|
Changes in the phenotype of effector/memory/virgin B and T cell populations and subtypes of Th and NK cell populations.
Time Frame: 1 year
|
T-cell response to SARS-CoV-2 will be analyzed by flow cytometry.
|
1 year
|
Incidence of symptomatic/asymptomatic COVID infection after revaccination.
Time Frame: 1 year
|
Confirmed COVID-19 is defined as the presence of at least one of the following symptoms: fever, new onset or increased cough, new onset or increased shortness of breath, chills, new onset or increased muscle pain, loss of taste or smell, sore throat, diarrhea or vomiting, combined with a respiratory specimen, obtained during the symptomatic period, positive for SARS-CoV-2 by nucleic acid amplification (PCR)-based testing or antigen testing.
|
1 year
|
Number of patients with hospital admissions and/or visits to the emergency department for severe symptoms related to COVID-19 infection.
Time Frame: 1 year
|
Confirmed COVID-19 is defined as the presence of at least one of the following symptoms: fever, new onset or increased cough, new onset or increased shortness of breath, chills, new onset or increased muscle pain, loss of taste or smell, sore throat, diarrhea or vomiting, combined with a respiratory specimen, obtained during the symptomatic period, positive for SARS-CoV-2 by nucleic acid amplification (PCR)-based testing or antigen testing.
|
1 year
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- REIN-TX
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on Janssen vaccine
-
Erasmus Medical CenterUniversity Medical Center Groningen; Academisch Medisch Centrum - Universiteit... and other collaboratorsRecruiting
-
Centre Hospitalier Universitaire de Saint EtienneActive, not recruiting
-
Federal University of Espirito SantoCentro de Pesquisas René Rachou; Secretaria de Estado da Saúde do Espírito...Not yet recruitingCOVID-19 | Vaccine Adverse Reaction | Vaccine-Preventable DiseasesBrazil
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
AstraZenecaCompleted
-
Alvea Holdings, LLCCompletedSars-CoV-2 InfectionSouth Africa
-
Qure Healthcare, LLCJohnson & Johnson Pharmaceutical Research & Development, L.L.C.CompletedDyspnea | Unexplained Chronic DyspneaUnited States
-
University of OxfordEnrolling by invitationTuberculosis | Covid-19 PandemicsThailand
-
China Medical University HospitalCompleted
-
Mark StegallJanssen Scientific Affairs, LLCActive, not recruitingKidney Transplant RecipientUnited States